Vivimed Labs Limited (VIVIMEDLAB) AI Stock Analysis

• Market Cap: ₹869.77M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): -0.58
• Revenue Growth: -22.42%
• EPS Growth: 21.83%
• Country: IN
• Employees: 607
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.88
• Shares Outstanding: 82,913,910
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.04
• Price to Book (P/B): -1.17
• Price to Sales (P/S): 0.35
• P/FCF Ratio: -4.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ₹12.00 ▲(142.42% Upside)

The score is driven down primarily by very weak financial performance (declining revenue, collapsing margins, losses, negative equity, and negative cash flows). Technicals are only moderately supportive with mixed trend signals and neutral momentum, while valuation is constrained by negative earnings and no stated dividend yield.

Positive Factors

Diversified business model

A multi-segment footprint across APIs, finished dosages and specialty chemicals provides structural diversification. This reduces dependency on any single end market, supports cross-selling, and helps stabilize revenues and capacity utilization over a multi-month horizon.

Contract manufacturing partnerships

Long-term manufacturing contracts and collaborations leverage in-house production capabilities and create recurring revenue streams. Such partnerships can lock in utilization, provide predictable volumes, and act as a durable revenue base versus one-off sales.

Export and licensing exposure

Exposure to international markets and licensing deals diversifies demand geographically and product-wise. Access to exports and licenses supports longer-term growth opportunities and cushions domestic cyclical weakness, aiding resilience over several months.

Negative Factors

Declining revenue and collapsing margins

Sustained revenue decline and a dramatic margin contraction indicate weakening pricing power, adverse product mix, or cost pressures. These impair operating leverage and the company's ability to generate profits or reinvest, harming long-term competitive positioning.

Negative equity and elevated leverage

Negative shareholder equity and extreme leverage raise solvency concerns and constrain strategic flexibility. High indebtedness limits access to affordable financing, increases refinancing risk, and can force asset sales or restructuring if cash flows don't recover.

Weak operating and free cash flow

Persistent negative operating and free cash flows undermine the company's ability to service debt, fund capex, or invest in growth without external financing. Deteriorating cash generation is a durable red flag for sustainability absent structural turnaround.

Vivimed Labs Limited Business Overview & Revenue Model

Company Description

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India.

How the Company Makes Money

Vivimed Labs generates revenue primarily through the sale of its pharmaceutical products, which include APIs and finished formulations for various therapeutic segments. Additionally, the company earns income from its specialty chemicals division, which supplies products to the personal care and cosmetics industries, as well as other industrial sectors. Key revenue streams include contract manufacturing partnerships and collaborations with major pharmaceutical companies, enabling Vivimed to leverage its manufacturing capabilities and expertise. The company may also benefit from licensing agreements and export sales in various international markets, contributing to its overall financial performance.

Vivimed Labs Limited Financial Statement Overview

Summary

Income statement, balance sheet, and cash flow signals are severely weak: revenue is shrinking (-18.75%), margins have collapsed (gross margin down to 6.71%) with ongoing losses, the balance sheet shows negative equity and elevated leverage/solvency risk, and operating/free cash flows are negative with sharply deteriorating free cash flow growth (-145.86%).

Income Statement

Vivimed Labs Limited has faced significant challenges in its income statement metrics. The company has experienced a consistent decline in revenue over the years, with a notable revenue growth rate of -18.75% in the most recent year. Gross profit margins have deteriorated sharply from 58.85% in 2021 to 6.71% in 2025, indicating a severe decline in profitability. Net profit margins have remained negative, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and financial distress.

Balance Sheet

The balance sheet of Vivimed Labs Limited reveals a precarious financial position. The company has a negative stockholders' equity in recent years, resulting in an alarming debt-to-equity ratio of -10.70 in 2025. This indicates a high level of financial leverage and potential solvency issues. The return on equity is negative, reflecting the company's inability to generate returns for shareholders. The equity ratio has also been negative, underscoring the company's reliance on debt financing.

Cash Flow

Vivimed Labs Limited's cash flow metrics show significant challenges. The company has experienced negative operating and free cash flows in recent years, with a free cash flow growth rate of -145.86% in 2025. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its losses. The free cash flow to net income ratio is positive, but this is due to the negative net income, which is not a positive indicator of financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	470.02M	1.16B	1.49B	1.87B	2.37B	8.61B
Gross Profit	114.72M	77.98M	705.71M	-928.65M	838.04M	5.07B
EBITDA	18.49M	-86.77M	-246.69M	-1.86B	-67.91M	336.05M
Net Income	-110.93M	-319.61M	-454.46M	-3.29B	-676.50M	-777.95M
Balance Sheet
Total Assets	0.00	9.21B	9.51B	9.88B	12.66B	12.89B
Cash, Cash Equivalents and Short-Term Investments	7.08M	7.08M	717.79M	37.62M	71.84M	64.31M
Total Debt	0.00	3.76B	3.79B	3.81B	2.78B	2.53B
Total Liabilities	351.69M	9.56B	9.56B	9.49B	9.02B	8.58B
Stockholders Equity	-351.69M	-351.69M	-54.61M	394.23M	3.64B	4.32B
Cash Flow
Free Cash Flow	0.00	-86.28M	-260.30M	303.54M	-6.75B	5.67B
Operating Cash Flow	0.00	-40.97M	-239.91M	138.12M	-6.58B	5.67B
Investing Cash Flow	0.00	-45.31M	282.88M	-49.68M	5.23B	4.04B
Financing Cash Flow	0.00	73.10M	-60.32M	-162.44M	-103.80M	-10.15B

Vivimed Labs Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIVIMEDLAB, the sentiment is Neutral. The current price of 4.95 is below the 20-day moving average (MA) of 15.33, below the 50-day MA of 9.07, and below the 200-day MA of 5.94, indicating a neutral trend. The MACD of 0.92 indicates Positive momentum. The RSI at 42.59 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:VIVIMEDLAB.

Vivimed Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALAXI	63 Neutral	₹280.90M	7.01	―	―	―	―
BIOFILCHEM	55 Neutral	₹525.64M	18.39	―	―	36.76%	433.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIVIMEDLAB	43 Neutral	₹869.77M	-3.57	―	―	-22.42%	21.83%
LASA	43 Neutral	₹547.61M	-1.51	―	―	-20.40%	-59.20%

Vivimed Labs Limited Corporate Events

Vivimed Labs’ Debt Assigned to Rare Asset Reconstruction Ltd.

Vivimed Labs Limited has announced that Rare Asset Reconstruction Ltd. has acquired the company’s financial assets from the State Bank of India. This transfer includes all underlying security interests, rights, and obligations, allowing Rare ARC to recover dues from Vivimed Labs, impacting the company’s financial restructuring and stakeholder obligations.